Home Cart Sign in  
Chemical Structure| 2184-96-5 Chemical Structure| 2184-96-5

Structure of 2184-96-5

Chemical Structure| 2184-96-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Bonakolluru, Yellaiah ; Marupati, Siddhartha ; Kandala, Satyanarayana ; Dasari, Gouthami ; Manchal, Ravinder ; Bandari, Srinivas

Abstract: In this paper, we report the synthesis of targeted quinoxaline-oxazole-morpholino conjugates (5a–n) in a conventional three-step procedure from 3-chloroquinoxalin-2(1H)-one. The anti-cancer activity was assessed against two human cancer cell lines, including MCF-7 (breast) and HepG2 (liver), using the MTT assay method. In this study, was used as the standard drug. The anticancer activity results show that the compounds5g (MCF-7 = 1.20 ± 0.10 and HepG2 = 1.04 ± 0.05 μM), 5f(MCF-7 = 1.29 ± 0.10 and HepG2 = 1.10 ± 0.06 μM), and 5e(MCF-7 = 1.72 ± 0.10 and HepG2 = 1.45 ± 0.12 μM) exhibited more potent anticancer activity as compared to the standard drug . In a cell survivability test (MCF-10A), all the three potent compounds (5g, 5f, and 5e) were evaluated against thenormal breast cell line, although neither of them displayed any significant cytotoxicity with IC50 values greater than 88.02 μM.In addition to this, molecular docking studies of compounds 5g, 5f, and 5e demonstrated that these compounds had moreEGFR-binding interactions. The potent compounds were further screened for their in vitro tyrosine kinase EGFR inhibitory activity using as the reference drug. The two compounds,5g and 5f, display the highest tyrosine kinase EGFR inhibitory potency than the reference . The active compounds 5g,5f, and 5e were subjected to in silico pharmacokinetic assessment by SWISS, ADME, and pkCSM. The three compounds, 5g, 5f, and 5e, followed Lipinski, Veber, Egan, and Muegge rules without any deviation.

Purchased from AmBeed:

Alternative Products

Product Details of [ 2184-96-5 ]

CAS No. :2184-96-5
Formula : C2H5Cl2NO
M.W : 129.97
SMILES Code : NCC(Cl)=O.[H]Cl

Safety of [ 2184-96-5 ]

Application In Synthesis of [ 2184-96-5 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 2184-96-5 ]

[ 2184-96-5 ] Synthesis Path-Downstream   1~1

  • 1
  • [ 2184-96-5 ]
  • [ 75747-14-7 ]
  • [ 857402-39-2 ]
YieldReaction ConditionsOperation in experiment
19% Example 14: Preparation of Glycine Co-Salt of the Hydroquinone of 17- AAG[0086] <strong>[75747-14-7]17-AAG</strong> (16.2 mg, 0.028 mmol, 1.0 equiv) was dissolved in 1.5 niL dichloromethane and stirred with a 10% aqueous solution of sodium hydrosulfite (1.5 rnL). The deep purple solution turned yellow after 5 min and the mixture was stirred for an additional 25 min. The organic layer was removed via syringe and the aqueous solution was extracted with an additional 0.30 mL dichloromethane. The combined organic solutions were washed with brine (1.0 mL) and then added directly to a solution of the acid chloride hydrochloride (3.4 mg, 0.03 mmol, 1.1 equiv) in 0.20 mL dichloromethane. The reaction mixture was stirred for 2 h and poured into a separatory funnel with 3.0 mL water. The organic layer was extracted and then washed with additional 2.0 mL water. The combined aqueous layers were lyophilized to yield 15 as a white fluffy powder (3.1 mg, 0.0051 mmol, 19% yield, 3:1 mixtures of phenol regioisomers). The material was analyzed by 1U NMR in D2O and LC-MS.
17-Allylaminogeldanamycin (1) (16.2 mg, 0.028 mmol, 1.0 equiv) was dissolved in 1.5 mL dichloromethane and stirred with a 10% aqueous solution of sodium hydrosulfite (1.5 mL). The deep purple solution turned yellow after 5 min and the mixture was stirred for an additional 25 min. The organic layer was removed via syringe and the aqueous solution was extracted with an additional 0.30 mL dichloromethane. The combined organic solutions were washed with brine (1.0 mL) and then added directly to a solution of the acid chloride hydrochloride (3.4 mg, 0.03 mmol, 1.1 equiv) in 0.20 mL dichloromethane. The reaction mixture was stirred for 2 h and poured into a separatory funnel with 3.0 mL water. The organic layer was extracted and then washed with additional 2.0 mL water. The combined aqueous layers were lyophilized to yield 7 as a white fluffy powder (3.1 mg, 0.0051 mmol, 19% yield, 3: 1 mixtures of phenol regioisomers). The material was analyzed by IH NMR in D20 and LC-MS; Example 16 Crystallization of Hydroquinone Co-Salt Forms of <strong>[75747-14-7]17-AAG</strong> Compound 7 is dissolved in the minimal amount of MeOH and then EtOAc is slowly added drop wise until the turbidity persists. The mixture is then allowed to stand for 14 hours and then the solid is collected by filtration, washed with EtOAc and dried under reduced pressure.
 

Historical Records